Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSenti Biosciences Inc

Senti Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.1779 USD 0.00(0%)
Last update at 2026-11-03T21:00:00Z
VOLUME
256649
Market Cap
9.36M

Momentum Score

…

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.17
Low
0.19
High
52 Week Price Range
0.29
Low
2.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.18
Dividend Yield
-
Revenue TTM
0.06M
Revenue Per Share
0.00
Gross Profit TTM
-31.27M
Debt / Equity
5.17
ROE
-466.46%
Net Debt
12.47M
ROCE
-164.94%
Diluted EPS TTM
-1.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -61.44M -52.79M -83.41M -58.21M -55.32M
Net income -61.44M -52.79M -71.06M -45.79M -55.33M
Selling general administrative 26.16M 23.51M 34.87M 40.85M 21.25M
Selling and marketing expenses - - 4.18M - -
Gross profit -3.62M - 1.98M 4.29M 2.29M
Reconciled depreciation 3.64M 5.85M 4.90M 3.92M 3.01M
Ebit -61.44M -60.73M -66.77M -74.55M -40.45M
Ebitda -57.80M -54.88M -61.34M -70.63M -37.41M
Depreciation and amortization 3.64M 5.85M 5.43M 3.92M 3.03M
Non operating income net other - - - 10.72M -
Operating income -63.73M -61.04M -92.73M -70.63M -40.45M
Other operating expenses 63.75M 61.04M 94.70M 74.92M 42.74M
Interest expense - - - -3.92M 0.01M
Interest income 0.93M 0.95M 3.57M 1.70M 0.01M
Net interest income 0.93M 0.95M 3.57M 1.70M 0.01M
Income tax expense - - 9.51M -12.42M 0.01M
Total revenue 0.02M 0.00M 1.98M 4.29M 2.29M
Total operating expenses 60.11M 61.04M 94.70M 74.92M 42.74M
Cost of revenue 3.64M - 5.24M - -
Total other income expense net 2.29M 8.25M 9.32M 12.42M -14.87M
Net income from continuing ops -61.44M -52.79M -88.25M -58.21M -55.32M
Net income applicable to common shares - - - -58.21M -55.32M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 51.22M 97.84M 119.48M 180.79M 96.70M
Other current assets 5.26M 8.88M 17.57M 0.10M 1.07M
Total liab 45.63M 72.19M 52.57M 53.53M 208.16M
Total stockholder equity 5.59M 25.65M 66.91M 127.26M -111.46M
Other current liab 5.35M 6.28M 6.30M 13.00M 5.96M
Common stock 0.00M 0.00M 0.01M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.01M 0.00M 0.00M
Retained earnings -358.57M -297.13M -244.34M -173.29M -115.08M
Other liab - - - 0.37M 0.80M
Other assets - - 0.00M 3.66M 3.43M
Cash 16.42M 48.28M 35.93M 57.62M 56.03M
Total current liabilities 13.97M 13.15M 12.67M 18.05M 14.54M
Current deferred revenue 0.35M 0.66M 0.99M 0.80M 1.66M
Net debt 12.47M -14.64M 1.74M -20.53M -33.30M
Short term debt 5.33M 4.75M 4.13M 1.99M 1.74M
Short long term debt total 28.89M 33.64M 37.67M 37.09M 22.73M
Other stockholder equity 364.16M 322.78M 311.25M 119.75M 3.62M
Property plant equipment - - - 56.14M 33.08M
Total current assets 23.27M 58.96M 71.20M 102.58M 60.19M
Net tangible assets - - - 127.26M -111.46M
Short term investments - - 0.00M 40.94M -
Net receivables 1.59M 1.80M 17.70M 0.63M 0.48M
Inventory - 0.34M - 3.29M 2.60M
Accounts payable 2.94M 1.45M 1.25M 2.27M 5.19M
Accumulated other comprehensive income - - -119.48M 0.00M -
Common stock total equity - - - 0.00M -
Retained earnings total equity - - - -173.29M -
Non currrent assets other 0.02M 3.64M 2.03M 3.66M 3.43M
Non current assets total 27.95M 38.88M 48.28M 78.21M 36.51M
Capital lease obligations 28.89M 33.64M 37.67M 37.09M 22.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.03M -19.14M -40.59M -5.54M
Change to liabilities - - - 2.24M 1.22M
Total cashflows from investing activities -0.18M 0.03M 30.08M -81.96M -5.54M
Net borrowings - 0.00M -0.11M 5.17M -0.02M
Total cash from financing activities 11.76M 53.73M 0.78M 118.55M 68.44M
Change to operating activities - - - 14.87M -0.20M
Net income -61.44M -52.79M -71.06M -58.22M -55.32M
Change in cash -31.87M 12.37M -21.54M 1.70M 28.26M
Begin period cash flow 51.81M 39.45M 60.99M 59.29M 31.03M
End period cash flow 19.95M 51.81M 39.45M 60.99M 59.29M
Total cash from operating activities -43.44M -41.40M -52.40M -34.90M -34.63M
Issuance of capital stock 0.00M 49.06M 0.51M 0.73M 67.00M
Depreciation 3.64M 5.85M 5.43M 3.92M 3.01M
Other cashflows from investing activities 0.01M 0.06M 0.10M - -
Dividends paid - - 0.40M - 0.00M
Change to inventory - - - - -0.20M
Change to account receivables 0.21M -0.73M -0.93M -0.13M -0.40M
Sale purchase of stock - - 0.51M 0.20M -
Other cashflows from financing activities 3.05M 4.67M 0.38M 117.63M 68.44M
Change to netincome - - - 5.66M 17.06M
Capital expenditures 0.20M 0.03M 12.04M 41.37M 5.54M
Change receivables - - - -0.13M -
Cash flows other operating - - - 14.50M -
Cash and cash equivalents changes - - - 1.70M -
Change in working capital 3.56M 4.04M 4.67M 13.90M 0.61M
Stock based compensation 5.71M 1.75M 9.67M 16.39M 2.29M
Other non cash items 5.09M -0.26M -1.10M -10.89M 14.74M
Free cash flow -43.64M -41.42M -64.43M -76.27M -40.18M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SNTI
Senti Biosciences Inc		 -
-%		 0.18 - - 170.11 5.45 418.98 -0.28
NVO
Novo Nordisk A/S		 -0.24
0.61%		 40.20 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -21.28
3.85%		 531.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 12.10
1.26%		 973.36 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Senti Biosciences Inc

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

2 Corporate Drive, South San Francisco, CA, United States, 94080

650 239 2030

https://www.sentibio.com

39

Name Title Year Born
Dr. Timothy K. Lu M.D., Ph.D. Co-founder, CEO, Pres & Director 1981
Dr. Philip Lee Ph.D. Co-Founder & CTO 1982
Ms. Susan D. Berland Sr. Financial Exec. & Independent Director 1955
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director 1966
Dr. Wilson Wong Ph.D. Scientific Co-Founder & Member of Scientific Advisory Board NA
Dr. Deborah A. Knobelman Ph.D. CFO & Treasurer 1974
Dr. Kanya Rajangam M.D., Ph.D. Chief Medical & Devel. Officer 1973
Susan Kahlert Controller NA
Dr. Timothy K. Lu M.D., Ph.D. Co-founder, CEO, President & Director 1981
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…